Vital Signs - Drug Development Focus on Genetically Modified Swine

Vital Signs - Drug Development Focus on Genetically Modified Swine

Modified Swine Hold out Promise of Improving Pre-Clinical Efficacy, Lowering Multi-billion Dollar Drug and Device Development Costs

RELEASE DATE
18-Mar-2016
REGION
North America
Research Code: 9A35-00-47-00-00
SKU: LS00158-NA-MR_17052

$450.00

Special Price $337.50 save 25 %

In stock
SKU
LS00158-NA-MR_17052

$450.00

$337.50 save 25 %

DownloadLink

Pay by invoice

ENQUIRE NOW

Description

The US pharmaceutical industry spends approximately $100 billion annually to develop new pharmaceutical drugs and medical devices. Today, a new drug takes approximately 15 years and over $1 billion to bring to market. Product development costs could be greatly reduced by using animal models that more closely resemble humans in their disease states and their physiological responses to treatment. Swine have been increasingly used as the animal model of choice because their anatomy, genetics, and physiology are more similar to humans than traditional animal models such as mice.

Table of Contents

February 2016 Issue

Related Research
The US pharmaceutical industry spends approximately $100 billion annually to develop new pharmaceutical drugs and medical devices. Today, a new drug takes approximately 15 years and over $1 billion to bring to market. Product development costs could be greatly reduced by using animal models that more closely resemble humans in their disease states and their physiological responses to treatment. Swine have been increasingly used as the animal model of choice because their anatomy, genetics, and physiology are more similar to humans than traditional animal models such as mice.
More Information
No Index No
Podcast No
Author Jane Andrews, Ph.D.
WIP Number 9A35-00-47-00-00
Is Prebook No